Ymmunobio AG is a preclinical stage biotechnology company developing a novel class of immune oncology therapeutic antibodies. The proprietary CEACAM antibodies have a direct co-stimulatory effect on immune cells by improving cell-cell communication. The proprietary antibodies are based on the research of Prof. Singer, University of Duisburg/Essen, Germany, which has been described in several Nature publications.
Since inception in 2021 the company has demonstrated anti-tumor activity of its lead asset YB-200 in validated models showing a clear correlation of the anti-tumor activity with changes in the immune compartment of the tumor micro environment. The start up was founded by Dr. Katrin Rupalla, a senior drug development expert and Prof. Singer is the lead scientist of Ymmunobio
Contact
